Curis Lifesciences (NSE:CURIS) EBIT: ₹107.0 Mil (TTM As of Mar. 2026)


NSE:CURIS Curis Lifesciences Ltd NSE:CURIS
19 GF Score
Price ₹101.50
! 2 Warning Signs
View Full Analysis

What is Curis Lifesciences EBIT?

Curis Lifesciences NSE:CURIS -0.49% 19 EBIT is ₹107.0 Mil as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Curis Lifesciences's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹107.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹107.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Curis Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 was 16.03%. Curis Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 24.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Curis Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.83%.

Curis Lifesciences  (NSE:CURIS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Curis Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=105.494 * ( 1 - 27.66% )/( (357.48 + 594.886)/ 2 )
=76.3143596/476.183
=16.03 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=425.347 - 64.831 - ( 3.036 - max(0, 175.771 - 312.926+3.036))
=357.48

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=815.207 - 88.67 - ( 131.651 - max(0, 274.034 - 691.405+131.651))
=594.886

Note: The Operating Income data used here is one times the annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Curis Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=107.001/( ( (110.098 + max(212.21, 0)) + (121.045 + max(439.892, 0)) )/ 2 )
=107.001/( ( 322.308 + 560.937 )/ 2 )
=107.001/441.6225
=24.23 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(75.236 + 183.997 + 47.557) - (64.831 + 0 + 29.749)
=212.21

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(112.226 + 341.088 + 100.498) - (88.67 + 0 + 25.25)
=439.892

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Curis Lifesciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=107.001/904.828
=11.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Lifesciences EBIT Related Terms

Curis Lifesciences EBIT Historical Data

* Premium members only.

The historical data trend for Curis Lifesciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Lifesciences EBIT Chart

Curis Lifesciences Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EBIT
35.18 80.22 100.94 107.00

Curis Lifesciences Semi-Annual Data
Mar23 Mar24 Mar25 Mar26
EBIT 35.18 80.22 100.94 107.00

NSE:CURIS vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curis Lifesciences EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curis Lifesciences's EV-to-EBIT falls into.


NSE:CURIS
19GF Score
Curis Lifesciences Ltd NSE:CURIS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Lifesciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹107.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹107.0 Mil mean?
Curis Lifesciences (NSE:CURIS) has a EBIT of ₹107.0 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curis Lifesciences.
Is Curis Lifesciences' EBIT too high?
Curis Lifesciences' current EBIT is ₹107.0 Mil. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' EBIT compare to ZTS and UTHR?
Curis Lifesciences' EBIT of ₹107.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curis Lifesciences. Curis Lifesciences's current EBIT is ₹107.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current EBIT of ₹107.0 Mil. The current EBIT is ₹107.0 Mil. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current EBIT is ₹107.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curis Lifesciences Business Description

Address PF-23, GIDC Sanand - II, Industrial Acme Pharma, Opposite Teva Pharma, Sanand, Ahmedabad, GJ, IND, 382110
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score

Get the complete analysis for NSE:CURIS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹101.50
Price